The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CSTL | +33.7% | -58.7% | -16.21% | +26% |
| S&P | +17.78% | +74.31% | +11.75% | +126% |
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
The genetic-testing company beat expectations with its Q2 results.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $87.01M | 0.8% |
| Gross Profit | $66.02M | 1.2% |
| Gross Margin | 75.87% | 0.3% |
| Market Cap | $1.14B | 52.1% |
| Market Cap / Employee | $1.29M | 0.0% |
| Employees | 883 | 16.0% |
| Net Income | -$2,332.00K | -124.3% |
| EBITDA | -$50.00K | -100.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $116.73M | -2.5% |
| Accounts Receivable | $43.38M | -15.3% |
| Inventory | 10.3 | 26.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $35.17M | 44.1% |
| Short Term Debt | $1.84M | -9.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -4.15% | -7.7% |
| Return On Invested Capital | -7.33% | -0.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $19.75M | -15.9% |
| Operating Free Cash Flow | $26.93M | -13.3% |
| Metric | Q3 2024 | Q4 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 142.67 | 43.48 | - | ||
| Price to Book | 1.25 | 1.34 | 1.45 | 2.43 | 43.69% |
| Price to Sales | 1.65 | 1.74 | 1.93 | 3.31 | 36.77% |
| Price to Tangible Book Value | 1.63 | 1.63 | 1.88 | 3.11 | 37.70% |
| Price to Free Cash Flow TTM | 11.82 | 14.63 | 20.65 | 40.28 | 116.35% |
| Enterprise Value to EBITDA | 176.17 | -435.76 | -137.75 | -17571.27 | -32157.30% |
| Free Cash Flow Yield | 8.5% | 6.8% | 4.8% | 2.5% | -53.78% |
| Return on Equity | -1.2% | -2.2% | -2.7% | -5.2% | -221.03% |
| Total Debt | $25.84M | $37.35M | $37.14M | $37.02M | 39.97% |
No podcast episodes available.
CSTL earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
